Cargando…
Disease-drug and drug-drug interaction in COVID-19: Risk and assessment
COVID-19 is announced as a global pandemic in 2020. Its mortality and morbidity rate are rapidly increasing, with limited medications. The emergent outbreak of COVID-19 prompted by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) keeps spreading. In this infection, a patient's immun...
Autores principales: | Kumar, Devendra, Trivedi, Neerja |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Masson SAS.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078916/ https://www.ncbi.nlm.nih.gov/pubmed/33940506 http://dx.doi.org/10.1016/j.biopha.2021.111642 |
Ejemplares similares
-
Evaluation of the synergistic effect of Allium sativum, Eugenia jambolana, Momordica charantia, Ocimum sanctum, and Psidium guajava on hepatic and intestinal drug metabolizing enzymes in rats
por: Kumar, Devendra, et al.
Publicado: (2016) -
Risk Assessment of Drug‐Induced Long QT Syndrome for Some COVID‐19 Repurposed Drugs
por: Michaud, Veronique, et al.
Publicado: (2020) -
Pharmacokinetic Drug–Drug Interactions among Antiepileptic Drugs, Including CBD, Drugs Used to Treat COVID-19 and Nutrients
por: Karaźniewicz-Łada, Marta, et al.
Publicado: (2021) -
Drug-drug interactions in patients with COVID-19
Publicado: (2020) -
Drug‐drug interactions with candidate medications used for COVID‐19 treatment: An overview
por: Rezaee, Haleh, et al.
Publicado: (2021)